Collegium Pharmaceutical (COLL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Collegium Pharmaceutical

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$22.75-0.17(-0.01%)Pre-market

Market Cap

$726.47M

P/E

15.2x

P/S

0.9x

P/B

2.3x

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

How this company scores

WeakMetricSide Score: 72/100

Grade capped at D — Interest coverage below 1× (0.2x) — earnings cannot cover interest. Strongest: Cash & Earnings Quality (24/25); weakest: Balance Sheet & Red Flags (5/25).

Profitability21/25

Growth22/25

Balance Sheet & Red Flags5/25

Cash & Earnings Quality24/25

Strengths

Rising free cash flowStrong marginsHigh ROERising earnings

Grade capped at D

Interest coverage below 1× (0.2x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 15.2x5y range 12.6x – 145.1x

Currently near its 15-quarter median.

P/S · 0.9x5y range 0.9x – 4.8x

Currently below its 20-quarter median.

P/B · 2.3x5y range 2.3x – 7.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Leverage Risk

Red Flag

D/E ratio is 3.3 — heavily leveraged and vulnerable to rising rates or cash flow dips.

Price & Volume

Market Cap $726.47M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $808.21M
Q. Revenue: $199.88M
TTM EBITDA: $391.04M
TTM Op. Income: $157.44M
Q. Op. Income: $3.70M
TTM Net Income: $47.91M
Q. Net Income: $-15.05M
EPS: $-0.46
Shares Out.: $32.46M

$808.21M in TTM revenue grew 14.3% YoY, reaching $199.88M last quarter. TTM EBITDA of $391.04M and TTM operating income of $157.44M show growth is flowing through to the bottom line. TTM net income of $47.91M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 55.2%
EBITDA Margin: 34.3%
Op. Margin: 1.9%
Net Margin: -7.5%

Op. margin of 1.9% is down 16.8% YoY — costs are rising relative to revenue. Net margin at -7.5% and gross margin of 55.2% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 15.2x
P/S Ratio: 0.9x
P/B Ratio: 2.3x

At 15.2x P/E, the stock trades within typical market levels. P/S of 0.9x and P/B of 2.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 42% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.14B
Cash: $129.47M
Long-Term Debt: $1.04B
Book Value: $311.91M
D/E Ratio: 3.3
Debt/EBITDA: 15.1

With $2.14B in assets and $1.04B in long-term debt, D/E is 3.3and book value is $311.91M — elevated leverage, meaning significant financial risk in a downturn. Over the past year, debt/equity is up 2% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $71.32M
TTM Free Cash Flow: $328.28M
FCF Margin: 40.6%
FCF / Net Income: 6.9

TTM FCF of $328.28M on $71.32M in operating cash flow. The FCF / Net Income ratio of 6.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 63% — a weakening trend.